Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Boosting mRNA Loading in Kidney-Targeted Nanoparticles: Exci
2026-06-11
This study systematically investigates how incorporating various excipients can enhance the mRNA loading capacity of polymeric mesoscale nanoparticles designed for kidney-targeted delivery. By testing agents such as 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), trehalose, and calcium acetate, the research addresses technical limitations in mRNA encapsulation, with direct implications for improving nanoparticle-based renal therapeutics.
-
Trametinib (GSK1120212) for MEK-ERK Pathway Modulation in On
2026-06-11
Trametinib (GSK1120212) stands out as a precise MEK1/2 inhibitor, enabling robust cell cycle G1 arrest and apoptosis induction in both cancer and disease models. Its validated effect in B-RAF mutated and resistant cell lines, alongside new insights from autoimmune disease research, position it as a versatile, high-impact oncology research tool.
-
Small Molecule Activation of BAK: SJ572946 as a Tool for Apo
2026-06-10
Sekar et al. report the discovery of SJ572946, a small molecule that directly activates the BCL-2 effector BAK to initiate apoptosis. This work provides a new approach for dissecting mitochondrial outer membrane permeabilization, with relevance for cancer research and the broader study of apoptosis mechanisms.
-
Axitinib (AG 013736): Precision Angiogenesis Inhibition in C
2026-06-10
Axitinib (AG 013736) sets the benchmark for selective VEGFR inhibition in both in vitro and in vivo cancer research. This article details workflow enhancements, troubleshooting strategies, and experimental advantages, translating the latest in vitro drug response metrics into actionable protocols for robust angiogenesis and tumor growth inhibition studies.
-
EZ Cap™ Mouse IL-12 mRNA (m1Ψ): Precision Immunotherapy Work
2026-06-09
EZ Cap™ Mouse IL-12 mRNA (m1Ψ) empowers researchers to deliver robust, extrahepatic cytokine expression, overcoming traditional mRNA delivery barriers. This guide demystifies advanced virus-mimicking nanoparticle workflows, protocol enhancements, and troubleshooting for optimized immunotherapy and gene expression research.
-
Necroptosis in Lung Epithelium: Ricin Toxin and Inflammatory
2026-06-09
Kempen et al. (2023) reveal that ricin toxin exposure leads to necroptosis in lung epithelial cells through bystander inflammatory signals from monocytic cells, driven by released factors such as HMGB1 and FasL. This study advances understanding of toxin-induced lung injury and highlights complexities in cell death pathways relevant to respiratory distress models.
-
Redefining Mitochondrial Dysfunction Assays: TMRE’s Strategi
2026-06-08
Translational researchers need robust, mechanistically precise tools to quantify mitochondrial membrane potential—a biomarker of bioenergetic health and a sentinel for disease-linked mitochondrial dysfunction. This article unpacks the mechanistic foundation of Tetramethylrhodamine ethyl ester perchlorate (TMRE, SKU: C8197), explores new evidence from trichothecene-induced oxidative stress models, benchmarks TMRE against competing probes, and delivers practical, protocol-level guidance for maximizing translational impact. Bridging foundational biochemistry with workflow optimization, this piece advances the conversation beyond standard product reviews and into actionable strategy for mitochondrial research.
-
Comparative Antibacterial Activities of N-Formimidoyl Thiena
2026-06-08
This study systematically compares the antibacterial spectrum and efficacy of N-formimidoyl thienamycin (MK0787) with recently developed β-lactam antibiotics, focusing on resistant clinical isolates. The findings clarify the relative strengths and limitations of these agents in overcoming β-lactamase-mediated resistance, informing antibiotic selection and assay design for resistance research.
-
Thiamet G and the O-GlcNAcylation Revolution in Translationa
2026-06-07
This thought-leadership article dissects how Thiamet G, a potent and selective O-GlcNAcase inhibitor, is transforming the translational research landscape by enabling precise modulation of O-GlcNAcylation. Integrating mechanistic insights from recent primary literature and cross-domain applications, we provide strategic guidance for researchers leveraging Thiamet G in disease modeling, especially in neurodegeneration, leukemia, and emerging bone biology. The discussion includes practical protocol parameters, a competitive research landscape, and a forward-looking perspective on O-GlcNAcylation's translational impact.
-
Poly-GA Drives Tau Pathology via ERK1/2: Inhibition with U01
2026-06-06
A recent study reveals that poly-glycine-alanine (poly-GA) from C9orf72 repeat expansions directly activates ERK1/2, promoting tau phosphorylation and neuronal cell death in cellular models of FTLD. Pharmacological inhibition of ERK1/2 with U0126 reverses these effects, highlighting a mechanistic link and potential therapeutic avenue for C9orf72-associated neurodegeneration.
-
Polyether Ionophore Toxicity: Mechanisms and Implications fo
2026-06-05
This review synthesizes clinical and molecular evidence on polyether ionophore toxicity, focusing on their ion transport mechanisms and relevance for drug repurposing. The findings clarify how structural features and transport modes underlie both therapeutic and adverse effects, informing safer research use in cancer and veterinary contexts.
-
GSK3 Inhibition as a Host-Directed Strategy Against Tubercul
2026-06-05
The referenced study demonstrates that inhibiting glycogen synthase kinase 3 (GSK3) in human macrophages significantly restricts intracellular growth of Mycobacterium tuberculosis (Mtb). This host-directed approach offers a promising alternative or adjunct to traditional antibiotic therapies, potentially reducing the risk of drug resistance and expanding therapeutic options for multi-drug resistant tuberculosis.
-
Polyethylenimine Linear for High-Efficiency DNA Transfection
2026-06-04
Polyethylenimine Linear (PEI), MW 40,000 enables reproducible, high-yield DNA transfection across scales, from 96-well plates to bioreactors, with robust performance in challenging cell lines. Recent advances in excipient-mediated payload loading empower innovative mRNA nanoparticle platforms, further expanding the reagent's impact.
-
Biomimetic mRNA Nanovaccines Target Neutrophils in Liver Can
2026-06-04
This study presents a biomimetic mRNA nanovaccine platform that selectively targets and activates tumor-associated neutrophils in hepatocellular carcinoma. By leveraging engineered CD300LD-coated liposomes and IL-36γ mRNA, the approach significantly enhances anti-tumor immunity and improves survival in preclinical models, demonstrating a promising avenue for next-generation immunotherapies.
-
Obeticholic Acid: FXR Agonism and New Horizons in Liver Fibr
2026-06-03
Explore the mechanistic depth of Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid) as a potent FXR agonist and its advanced applications in liver fibrosis research. This article uniquely bridges bile acid homeostasis modulation with emerging immunometabolic insights and practical protocol advances.